Posters

Micropulse laser as an adyuvant therapy of pharmacological intravitreal anti-VEGF and dexamethasone treatments, in macular edema associated with retinal vein occlusions

Poster Details

First Author: R.Cobo-Soriano SPAIN

Co Author(s):    I. Lozano-Escobar   J. Zarallo-Gallardo   P. Moreno-Martinez                       

Abstract Details



Purpose:

Macular edema associated with retinal vein occlusion disease, has a recurrent and chronic evolution during several years, needing repetitive intravitreal anti-VEGF and/or dexamethasone therapies. Micropulse Laser (MPL) macular photocoagulation has been published as a non-invasive and effective treatment in macular edema secondary to several retinal diseases. Macular edema associated with retinal vein occlusion disease, has a recurrent and chronic evolution during several years, needing repetitive intravitreal anti-VEGF and/or dexamethasone therapies. Micropulse Laser (MPL) macular photocoagulation has been published as a non-invasive and effective treatment in macular edema secondary to several retinal diseases.

Setting:

University Henares Hospital, Francisco de Vitoria University, Madrid, Spain.

Methods:

Descriptive retrospective case series.

Results:

Consecutive eyes with BRVO (n=12) and CRVO (n=3) treated with MPL associated with intravitreal anti-VEGF and/or dexamethasone therapy, during a nine-month period (2016), were retrospectively analyzed. LMP-532 nm grids were applied one-month after intravitreal anti-VEGF therapy, and two-months after intravitreal dexamethasone implant (Ozurdex®) during the dry stages of the macula, in order to combine two different therapeutic mechanisms and hold the pharmacological effect on. During the study period, 5 eyes had a single LMP treatment, 7 cases had two, and 3 eyes had ≥3 LMP treatments. The time between LMP therapy and the next treatment (LMP/ anti-VEGF/ dexamethasone), and evolution of central macular thickness (CMT) followed a very variable course depending of the severity of initial macular edema. Change of corrected visual acuity (BCVA) among pre-treatment (0.58 (0.2) LogMAR in BRVO, and 1.1(0.3) in CRVO), and post combined-therapies (0.34 (0.3) LogMAR in BRVO, and 0.43 (0.2) in CRVO) was statistically significant in both pathologies (p<0.05, paired Student t-test).

Conclusions:

Micropulse Laser associated with pharmacological intravitreal therapy (anti-VEGF and dexamethasone) in real life patients with macular edema associated with BRVO and CRVO, may play a role in extending the treatment intervals and in increasing the dry stages of the chronic edematous disease. Further prospective studies will determine if MPL diminish the number of intravitreal injections in the long time.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy